|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
|
US4394448A
(en)
|
1978-02-24 |
1983-07-19 |
Szoka Jr Francis C |
Method of inserting DNA into living cells
|
|
US4391904A
(en)
|
1979-12-26 |
1983-07-05 |
Syva Company |
Test strip kits in immunoassays and compositions therein
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4766075A
(en)
|
1982-07-14 |
1988-08-23 |
Genentech, Inc. |
Human tissue plasminogen activator
|
|
US5186941A
(en)
|
1983-05-06 |
1993-02-16 |
Vestar, Inc. |
Vesicle formulation for the controlled release of therapeutic agents
|
|
US4801542A
(en)
|
1984-10-12 |
1989-01-31 |
Zymogenetics, Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
GR860984B
(en)
|
1985-04-17 |
1986-08-18 |
Zymogenetics Inc |
Expression of factor vii and ix activities in mammalian cells
|
|
US4935349A
(en)
|
1986-01-17 |
1990-06-19 |
Zymogenetics, Inc. |
Expression of higher eucaryotic genes in aspergillus
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
GB2188637B
(en)
|
1986-02-07 |
1990-11-14 |
Oncogen |
Vaccines against melanoma
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US4866042A
(en)
|
1987-11-18 |
1989-09-12 |
Neuwelt Edward A |
Method for the delivery of genetic material across the blood brain barrier
|
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5672683A
(en)
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
US6018031A
(en)
|
1989-10-20 |
2000-01-25 |
Trustees Of Dartmouth College |
Binding agents specific for IgA receptor
|
|
US5932211A
(en)
|
1991-11-12 |
1999-08-03 |
Women's And Children's Hospital |
Glycosylation variants of iduronate 2-sulfatase
|
|
EP1136556B1
(en)
|
1991-11-25 |
2005-06-08 |
Enzon, Inc. |
Method of producing multivalent antigen-binding proteins
|
|
US5981194A
(en)
|
1992-07-10 |
1999-11-09 |
University Of British Columbia |
Use of p97 and iron binding proteins as diagnostic and therapeutic agents
|
|
WO1994001463A1
(en)
|
1992-07-10 |
1994-01-20 |
University Of British Columbia |
USE OF p97 AND IRON BINDING PROTEINS AS DIAGNOSTIC AND THERAPEUTIC AGENTS
|
|
US20020119095A1
(en)
|
1992-07-10 |
2002-08-29 |
Reinhard Gabathuler |
Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
|
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
ATE204325T1
(de)
|
1993-04-29 |
2001-09-15 |
Unilever Nv |
Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
|
|
CZ292061B6
(cs)
|
1994-03-17 |
2003-07-16 |
Merck Patent Gmbh |
Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
|
|
TW492882B
(en)
|
1997-11-28 |
2002-07-01 |
Caleb Pharmaceuticals Inc |
Cholinergic antagonist plaster composition
|
|
US6982089B2
(en)
|
1999-02-24 |
2006-01-03 |
Tact Ip, Llc |
Cytokine antagonists for neurological and neuropsychiatric disorders
|
|
US7214658B2
(en)
|
2004-07-06 |
2007-05-08 |
Tact Ip, Llc |
Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
|
|
US6015557A
(en)
|
1999-02-24 |
2000-01-18 |
Tobinick; Edward L. |
Tumor necrosis factor antagonists for the treatment of neurological disorders
|
|
US6419934B1
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
|
US6177077B1
(en)
|
1999-02-24 |
2001-01-23 |
Edward L. Tobinick |
TNT inhibitors for the treatment of neurological disorders
|
|
US6537549B2
(en)
|
1999-02-24 |
2003-03-25 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
US6419944B2
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
US6507788B1
(en)
|
1999-02-25 |
2003-01-14 |
Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) |
Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
|
|
US6642038B1
(en)
|
1999-09-14 |
2003-11-04 |
Genzyme Glycobiology Research Institute, Inc. |
GlcNAc phosphotransferase of the lysosomal targeting pathway
|
|
JP2003525038A
(ja)
|
2000-02-08 |
2003-08-26 |
ユニバーシティー オブ ブリティッシュ コロンビア |
治療薬をスクリーニングするための組成物および方法
|
|
US6261595B1
(en)
|
2000-02-29 |
2001-07-17 |
Zars, Inc. |
Transdermal drug patch with attached pocket for controlled heating device
|
|
AU2001255771B2
(en)
|
2000-05-01 |
2007-05-31 |
Biomarin Pharmaceutical Inc. |
Enzymes useful for treating and methods for treating MPS-VI and cell lines for producing such enzymes recombinantly
|
|
WO2002013843A2
(en)
|
2000-08-17 |
2002-02-21 |
University Of British Columbia |
Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
|
|
AU2001285020A1
(en)
|
2000-08-17 |
2002-02-25 |
Synapse Technologies, Inc. |
P97-active agent conjugates and their methods of use
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
CN100488563C
(zh)
|
2001-02-19 |
2009-05-20 |
默克专利有限公司 |
免疫原性降低的经修饰抗egfr抗体
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
AU2002345673B2
(en)
|
2001-06-13 |
2007-04-26 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
WO2003009815A2
(en)
|
2001-07-25 |
2003-02-06 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
|
ES2411007T3
(es)
|
2001-10-10 |
2013-07-04 |
Novo Nordisk A/S |
Remodelación y glicoconjugación de péptidos
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
US20050158296A1
(en)
|
2002-01-11 |
2005-07-21 |
Starr Christopher M. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
US7244592B2
(en)
|
2002-03-07 |
2007-07-17 |
Dyax Corp. |
Ligand screening and discovery
|
|
US7419811B2
(en)
|
2003-02-28 |
2008-09-02 |
The Board Of Trustees Of The University Of Illinois |
Use of specifically engineered enzymes to enhance the efficacy of prodrugs
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
CA2542099A1
(en)
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
|
CA2556245A1
(en)
|
2004-02-06 |
2005-08-25 |
Biomarin Pharmaceutical Inc. |
Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
US8236306B2
(en)
|
2004-12-18 |
2012-08-07 |
Edward Lewis Tobinick |
Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
|
|
EP1844073A1
(en)
|
2005-01-31 |
2007-10-17 |
Ablynx N.V. |
Method for generating variable domain sequences of heavy chain antibodies
|
|
US7842467B1
(en)
|
2005-05-12 |
2010-11-30 |
Celera Corporation |
Breast disease targets and uses thereof
|
|
PT1951759E
(pt)
|
2005-11-12 |
2010-04-01 |
Lilly Co Eli |
Anticorpos anti-egfr
|
|
KR101866623B1
(ko)
|
2005-11-28 |
2018-07-04 |
젠맵 에이/에스 |
재조합 1가 항체 및 그의 제조 방법
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
JP5959795B2
(ja)
|
2006-08-18 |
2016-08-02 |
アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. |
血液脳関門送達のための物質
|
|
EP2125024B1
(en)
|
2007-03-23 |
2013-02-13 |
TO-BBB Holding B.V. |
Targeted intracellular delivery of antiviral agents
|
|
US9365634B2
(en)
|
2007-05-29 |
2016-06-14 |
Angiochem Inc. |
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
|
US20110124576A1
(en)
|
2007-08-08 |
2011-05-26 |
Novozymes A/S |
Transferrin Variants and Conjugates
|
|
HUE035182T2
(hu)
|
2008-03-18 |
2018-05-02 |
Genentech Inc |
Anti-HER2 antitest-hatóanyag-konjugátum és pertuzumab kombinációi
|
|
HRP20190690T1
(hr)
|
2009-10-09 |
2019-06-28 |
Armagen, Inc. |
Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
|
|
DK2560687T3
(en)
|
2010-04-19 |
2017-09-18 |
Nlife Therapeutics S L |
Preparations and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
|
|
FR2959229B1
(fr)
|
2010-04-21 |
2013-01-18 |
Vect Horus |
Derives peptidiques, leur preparation et leurs utilisations
|
|
EP3103469B1
(en)
|
2010-06-25 |
2020-12-09 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of therapeutic agents
|
|
PL2593131T3
(pl)
|
2010-06-25 |
2020-01-31 |
Shire Human Genetic Therapies, Inc. |
Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
|
|
KR101535791B1
(ko)
|
2010-11-12 |
2015-07-10 |
주식회사 녹십자 |
개량형 이듀로네이트-2-설파타제 및 이의 용도
|
|
EP2717917B1
(en)
|
2011-07-05 |
2016-04-20 |
biOasis Technologies Inc |
P97-antibody conjugates
|
|
CA2842492A1
(en)
*
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
|
HK1202431A1
(en)
|
2012-05-02 |
2015-10-02 |
Symphogen A/S |
Humanized pan-her antibody compositions
|
|
US20140004097A1
(en)
*
|
2012-06-29 |
2014-01-02 |
Shire Human Genetic Therapies, Inc. |
Method of producing recombinant iduronate-2-sulfatase
|
|
CA3140358A1
(en)
*
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
US8753426B2
(en)
|
2012-08-03 |
2014-06-17 |
Air Products And Chemicals, Inc. |
Polymers, polymer membranes and methods of producing the same
|
|
JP2016503394A
(ja)
|
2012-10-26 |
2016-02-04 |
エヌライフ、セラピューティックス、ソシエダッド、リミターダNlife Therapeutics, S.L. |
細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法
|
|
AU2014243816B2
(en)
|
2013-03-13 |
2019-01-31 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
|
WO2015031673A2
(en)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
CA2935195A1
(en)
|
2014-02-03 |
2015-08-06 |
Bioasis Technologies, Inc. |
P97 fusion proteins
|
|
JP6605482B2
(ja)
|
2014-02-19 |
2019-11-13 |
バイオアシス テクノロジーズ インコーポレイテッド |
P97−ids融合タンパク質
|
|
EP3137610B1
(en)
|
2014-05-01 |
2019-03-06 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
|
CA3011382A1
(en)
|
2016-01-13 |
2017-07-20 |
Bioasis Technologies, Inc. |
Blood-brain barrier vector compounds and conjugates thereof
|